ETR:AFX Carl Zeiss Meditec (AFX) Stock Price, News & Analysis €56.95 +0.40 (+0.71%) (As of 12/2/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlines About Carl Zeiss Meditec Stock (ETR:AFX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Carl Zeiss Meditec alerts:Sign Up Key Stats Today's Range€56.10▼€57.6550-Day Range€54.65▼€71.1552-Week Range€54.60▼€123.75Volume75,796 shsAverage Volume94,405 shsMarket Capitalization$5.09 billionP/E Ratio24.98Dividend Yield1.93%Price TargetN/AConsensus RatingN/A Company OverviewCarl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.Read More… Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Receive AFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carl Zeiss Meditec and its competitors with MarketBeat's FREE daily newsletter. Email Address AFX Stock News HeadlinesUBS Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)November 26, 2024 | markets.businessinsider.comCarl Zeiss Meditec AG (AFX.SG)November 20, 2024 | uk.finance.yahoo.comUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonDecember 3, 2024 | Porter & Company (Ad)Carl Zeiss Meditec (ETR:AFX) Will Be Hoping To Turn Its Returns On Capital AroundNovember 1, 2024 | finance.yahoo.comIs Carl Zeiss Meditec AG's (ETR:AFX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?October 14, 2024 | finance.yahoo.comChesterfield-based tech and optics business makes $24M expansion, adds 40 jobsSeptember 30, 2024 | bizjournals.comZEISS introduces its latest Robotic Visualisation System for neuro surgerySeptember 30, 2024 | tmcnet.comWhat Is Carl Zeiss Meditec AG's (ETR:AFX) Share Price Doing?September 30, 2024 | finance.yahoo.comSee More Headlines AFX Stock Analysis - Frequently Asked Questions How have AFX shares performed this year? Carl Zeiss Meditec's stock was trading at €98.84 at the beginning of 2024. Since then, AFX shares have decreased by 42.4% and is now trading at €56.95. View the best growth stocks for 2024 here. What other stocks do shareholders of Carl Zeiss Meditec own? Based on aggregate information from My MarketBeat watchlists, some other companies that Carl Zeiss Meditec investors own include Intel (INTC), Meta Platforms (META), NVIDIA (NVDA), Volkswagen (VOW3), AbbVie (ABBV), Chevron (CVX) and Siemens Aktiengesellschaft (SIE). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolETR:AFX CUSIPN/A CIKN/A Webwww.zeiss.com Phone+49-3641-2200FaxN/AEmployees4,950Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)€2.28 Trailing P/E Ratio24.98 Forward P/E Ratio19.50 P/E Growth2.83Net Income$203.20 million Net Margins9.83% Pretax MarginN/A Return on Equity12.83% Return on Assets7.03% Debt Debt-to-Equity Ratio6.74 Current Ratio3.51 Quick Ratio2.47 Sales & Book Value Annual Sales$2.07 billion Price / Sales2.46 Cash Flow€0.04 per share Price / Cash Flow1,398.28 Book Value€23.42 per share Price / Book2.43Miscellaneous Outstanding Shares89,440,000Free FloatN/AMarket Cap$5.09 billion OptionableNot Optionable Beta0.98 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (ETR:AFX) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carl Zeiss Meditec AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Carl Zeiss Meditec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.